Trastuzumab Deruxtecan Garners Approval in Japan for HER2-Lo

Japan’s Ministry of Health, Labor and Welfare has approved fam-trastuzumab deruxtecan-nxki for the treatment of adult patients with HER2-low unresectable or recurrent breast cancer after prior chemotherapy.

Related Keywords

Japan , Wataru Takasaki , Daiichi Sankyo , Japan Ministry Of Health , Rd Division , Trastuzumab Deruxtecan , Her2 Low Metastatic Breast Cancer , Phase 3 Destiny Breast04 Trial , Japans Ministry Of Health , Labor And Welfare ,